Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.16, read 2026-10-23
Ethical does not pass the values gate
Price133.40 USD
Fair value69.98
Ethical score70.0/100
Our investment reviews on this name
2026-10-15Read Accumulation125.14+6.6% to today ✓Markup gives way to Accumulation after an 84% rise in 15 weeks
2026-07-02Read Markup68.19+95.6% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Rubrik Inc holds its Accumulation at $133.40. The statistical read favours the buyers, held for 15 days.
As held on the ledger · 2026-10-26
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 15 days
Price at the screen
$133.40
Valuation
N/A trailing · 173.69 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.12
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
41.33%
Below 33%
Interest-bearing debt is 41.3% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
46.83%
Below 33%
Interest-bearing cash and securities are 46.8% of assets, above the one-third limit.
Fail
Receivables
23.02%
Below 49%
Money owed to the company is 23.0% of assets, under the 49% limit.
Pass
Revenue purity
3.96%
Below 5%
Only 4.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Rubrik's business is in a permissible area, but its interest-bearing debt is about 41% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when RBRK's ethical verdict changes
Today RBRK does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-26 screen. The gold marker is the market price at the same screen. The price runs 47.5% above the base estimate.
Third-party analyst targets: 27 covering, consensus None. The average target sits −10% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Data safety priced well beyond its worth
Picture a firm that steps in when ransomware strikes and files vanish. Rubrik sells that service across cloud and on premise setups, yet the shares trade at nearly 80 dollars against a fair value near 54. Revenue climbs 39 percent, but the business still posts a 20 percent loss and carries a forward multiple above 121 times.
We pass because the numbers leave no margin for error. The narrow moat offers little defence if larger rivals cut in, and the price already bakes in flawless growth that has yet to turn into profit. Analyst targets sit higher still, yet our valuation shows the market has run ahead of the cash flows.
High expectations create the real risk here. Any slowdown in new customer wins or a shift in spending priorities could compress the multiple fast. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RBRK trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-22Accumulation$113.90-9.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 9.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 55% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (28 analysts) rates it strong buy, with a mean price target of $96. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 17.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (28 analysts) rates it strong buy, with a mean price target of $96. Insiders have been net sellers over the past quarter.
2026-10-02Markup$106.71+4.4%Entry 13
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (28 analysts) rates it strong buy, with a mean price target of $96. Insiders have been net sellers over the past quarter. Since the last review it its composite score eased.
2026-08-27Markup$102.23+0.0%Entry 12
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (28 analysts) rates it strong buy, with a mean price target of $96. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-26Markup$102.23+0.0%Entry 11
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (28 analysts) rates it strong buy, with a mean price target of $96. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-25Markup$102.23+0.0%Entry 10
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (28 analysts) rates it strong buy, with a mean price target of $96. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-24Markup$102.23+0.0%Entry 9
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (28 analysts) rates it strong buy, with a mean price target of $96. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-23Markup$102.23+0.0%Entry 8
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (28 analysts) rates it strong buy, with a mean price target of $96. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-22Markup$102.23+0.0%Entry 7
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (28 analysts) rates it strong buy, with a mean price target of $96. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-21Markup$102.23+0.0%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (28 analysts) rates it strong buy, with a mean price target of $96. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
